Legal Opinion
In re Lupron Marketing & Sales Practices Litigation
District Court, D. Massachusetts
Decided May 12, 2005No. Master File No. 01-CV-10861-RGS; MDL NO. 1430PublishedCited by 40 opinions
1Opinion of the Court
MEMORANDUM AND ORDER APPROVING SETTLEMENT AND CERTIFYING THE CLASS
STEARNS, District Judge.
This aspiring Multi-District Litigation (MDL) class action was brought by patients, health care plans, and insurers seeking damages incurred because of an alleged scheme orchestrated by TAP Pharmaceutical Products, Inc. (TAP) to inflate the retail price of the prescription drug Lupron®.1 Plaintiffs’ principal claims are based on the civil provisions of the Racketeer Influenced and Corrupt Organizations Act (RICO), 18 U.S.C. § 1962, and various state consumer protection statutes. On November 24, 2004, the…
2Cases cited31 opinions
- Amchem Products, Inc. v. WindsorSupreme Court of the United States · 1997
- Neder v. United StatesSupreme Court of the United States · 1999
- Sedima, S. P. R. L. v. Imrex Co.Supreme Court of the United States · 1985
- Eisen v. Carlisle & JacquelinSupreme Court of the United States · 1974
- Missouri v. Jenkins Ex Rel. AgyeiSupreme Court of the United States · 1989
26 more not listed; retrieve them via the Exa API.
3Cited by40 opinions
- Sullivan v. DB Investments, Inc.Court of Appeals for the Third Circuit · 2011
- In re Pharmaceutical Industry Average Wholesale Price LitigationDistrict Court, D. Massachusetts · 2005
- Donovan v. Philip Morris USA, Inc.District Court, D. Massachusetts · 2010
- In re Relafen Antitrust LitigationDistrict Court, D. Massachusetts · 2005
- In Re Lupron Marketing and Sales Practices Litig.Court of Appeals for the First Circuit · 2012
35 more not listed; retrieve them via the Exa API.